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Abstract 
The transmembrane glycoprotein CD26 or dipeptidyl peptidase IV (DPPIV) is a 
multifunctional protein. In immune system, CD26 plays a role in T-cell function and is 
also involved in thymic maturation and emigration patterns. In preclinical studies, 
treatment with DPPIV inhibitors reduces insulitis and delays or even reverses the new -
onset of type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. However, the 
specific mechanisms involved in these effects remain unknown. The aim of the present 
study was to investigate how DPPIV inhibition modifies the expression of genes in the 
thymus of NOD mice by microarray analysis. Changes in the gene expression of β-cell 
autoantigens and Aire in thymic epithelial cells (TECs) were also evaluated by using 
qRT-PCR. A DPPIV inhibitor, MK626, was orally administered in the diet for 4 and 6 
weeks starting at 6-8 weeks of age. Thymic glands from treated and control mice were 
obtained for each study checkpoint. Thymus transcriptome analysis revealed that 58 
genes were significantly over-expressed in K626-treated mice after 6 weeks of 
treatment. Changes in gene expression in the thymus were confined mainly to the 
immune system, including innate immunity, chemotaxis, antigen presentation and 
immunoregulation. Most of the genes are implicated in central tolerance mechanisms 
through several pathways. No differences were observed in the expression of Aire and 
β-cell autoantigens in TECs. In the current study, we demonstrate that treatment with 
the DPPIV inhibitor MK626 in NOD mice alters the expression of the immune 
response-related genes in the thymus, especially those related to immunological central 
tolerance, and may contribute to the prevention of T1D. 
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 32 
1. Introduction 33 
Type 1 diabetes (T1D) is a chronic autoimmune disease caused by the selective 34 
destruction of pancreatic β cells (Atkinson and Eisenbarth, 2001). The breakdown of 35 
immune self-tolerance homeostasis to pancreatic islet β cells is now recognized as the 36 
essential cause for the development of the diabetogenic autoimmune response (Geenen, 37 
2012). Therefore, the reestablishment of autoimmune tolerance state toward self-38 
antigens (Ags) is one of the primary objectives for the prevention of autoimmune 39 
diseases, including T1D. During the last decade, immunotherapeutic innovative 40 
strategies have focused on maintaining and restoring self-tolerance to pancreatic β cells 41 
in T1D (Staeva et al., 2013). 42 
CD26, also known as dipeptidyl peptidase IV (CD26/DPPIV), is a 43 
multifunctional cell surface glycoprotein expressed on a variety of cell types, including 44 
immune cells. This protein is a proteolytic enzyme, receptor and co-stimulatory protein 45 
and is involved in adhesion and apoptosis (Boonacker, 2003). CD26/DPPIV’s 46 
proteolytic activity is capable of cleaving N-terminal dipeptides from polypeptides with 47 
either proline or alanine residues in the penultimate position, modulating the activity of 48 
biologically relevant peptides such as cytokines, chemokines and incretins, among 49 
others. In addition, several studies have highlighted the important role of CD26/DPPIV 50 
in T cell activation and its involvement in immune responses (Morimoto and 51 
Schlossman, 1998). CD26/DPPIV interacts with molecules such as adenosin deaminase 52 
and CD45 and is able to modulate the co-stimulation and proliferation of activated T 53 
cells (Ohnuma et al., 2008).  54 
Inhibition of CD26/DPPIV suppresses antigen-stimulated T cell proliferation 55 
and cytokine production, thus suggesting a potential application for DPPIV inhibitors as 56 
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immunomodulatory drugs in autoimmune diseases (Biton et al., 2011). The effect of 57 
treatment with a CD26/DPPIV inhibitor on the immune system has been recently 58 
evaluated in several animal models of inflammatory human diseases (Steinbrecher et al., 59 
2011). In relation to T1D, treatment with CD26/DPPIV inhibitors has been shown to 60 
delay the onset of the disease as well as even to reverse new-onset diabetes in non-obese 61 
diabetic (NOD) mice, in both cases with an associated reduction in the islet lymphocyte 62 
infiltration (Ding et al., 2014; Jelsing et al., 2012; Tian et al., 2010) although the exact 63 
mechanism is unknown. Treatment with a CD26/DPPIV inhibitor was also described to 64 
modify T lymphocyte subsets with an increase in the percentage of regulatory T cells 65 
(Tregs) in the peripheral and thymic compartments (Tian et al., 2010). Moreover, in the 66 
NOD model, treatment with the CD26/DPPIV inhibitor sitagliptin has been reported to 67 
preserve islet transplants through a pathway involving modulation of CD4+ T cell 68 
migration (Kim et al., 2009). We recently demonstrated that treatment with the 69 
CD26/DPPIV inhibitor MK626 decreases the incidence of type 1 diabetes (T1D) by 70 
31% and reduces insulitis in the pre-diabetic NOD mouse model. No differences were 71 
observed in the percentage of T cell subsets from peripheral and central compartments 72 
between treated and control mice. However, MK626 treatment significantly increased 73 
the expression of CD26 in CD8+ T effector memory (TEM) T cells as well as their 74 
proliferative capacity and cytokine secretion. In vitro assays suggested an 75 
immunosuppressive role for CD8+ TEM cell subset that may be involved in the protection 76 
against autoimmunity to β pancreatic islets associated to CD26/DPPIV inhibitor 77 
treatment (Alonso et al., 2015). 78 
There is now evidence that a failure in thymus-dependent central tolerance to 79 
pancreatic β cells plays a primary role in T1D pathogenesis (Geenen, 2012). The 80 
thymus is the organ responsible for the establishment of immunological central 81 
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tolerance by the deletion of self-reactive T cells through positive and negative selection 82 
mechanisms. Defects in the negative selection of self-reactive T cells in the NOD 83 
thymus have been reported (Kishimoto and Sprent, 2001). On the other hand, medullary 84 
thymic epithelial cells (mTEC) can express a broad range of tissue-restricted Ags 85 
(TRAs) (Derbinski et al., 2001; Fornari et al., 2010; Gillard and Farr 2006; Kyewski et 86 
al., 2002; Oliveira et al., 2013; Sospedra et al., 1998; Tykocinski et al., 2010), also 87 
known as “promiscuous gene expression”, that imposes T cell tolerance and protects 88 
from autoimmune disease (Sospedra et al., 1998). 89 
In the thymus, CD26/DPPIV has been shown to play a role in the differentiation 90 
and maturation of thymocytes, whose impairment has remarkable effects on lymphocyte 91 
subsets and thymic architecture (Klemman et al., 2009). Moreover, CD26/DPPIV has 92 
been proposed as a mediator of intrathymic lymphocyte migration and may play a role 93 
in thymic deletion of emerging clones (Ruiz et al., 1996) thus implying a possible role 94 
for CD26/DPPIV in the establishment of central tolerance.  95 
To our knowledge, this is the first report that describes the effect of treatment 96 
with a CD26/DPPIV inhibitor on the thymus transcriptome in the NOD mice and 97 
hypothesizes its possible involvement in the modification of the expression of genes 98 
related to central tolerance mechanisms. Here, we investigated the impact of treatment 99 
with the CD26/DPPIV inhibitor MK626 on the thymic gene expression profile of pre-100 
diabetic NOD mice by DNA microarray technique, with particular emphasis on those 101 
genes involved in the immune response. We also evaluated the effects of MK626 102 
treatment on islet autoantigens and Aire gene expression in thymic epithelial cells by 103 
qRT-PCR. 104 
105 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 6
 106 
2. Materials and methods  107 
2.1. Mice  108 
Wild-type NOD mice were obtained from our colony established with mice from the 109 
Jackson Laboratory (Bar Harbor, ME, USA). Only females were used for this study. 110 
Mice were kept under specific pathogen-free conditions and monitored daily for 111 
diabetes onset. At the end of the study, mice were sacrificed by cervical dislocation. 112 
This study was carried out in strict accordance with the recommendations in the Guide 113 
for the Care and Use of Laboratory Animals of the Generalitat de atalunya, Catalan 114 
Government. The protocol was approved by the Committee on the Ethics of Animal 115 
Experiments of the Germans Trias i Pujol Research Institute (Permit number: DAAM 116 
5928). 117 
 118 
2.2. Treatment with MK626 119 
Female NOD/Ltj mice were placed on either a normal chow diet (Research Diets, Inc, 120 
New Brunswick, NJ) or the same diet containing the CD26/DPPIV inhibitor MK626 121 
(21 mg/kg of diet), kindly donated by Dr. James Mu (Merck Research Laboratories, 122 
New Jersey, USA), for 4 and 6 weeks starting at 6-8 weeks of age (pre-diabetic stage). 123 
The CD26/DPPIV inhibitor used in this study, MK626, was a des-fluoroanalog of 124 
sitagliptin (Kim et al., 2005). The treatment protocol is based on previous studies 125 
published in the literature using DPPIV inhibitors in experimental diabetes (Jelsing J et 126 
al., 2012; Kim D et al, 2005; Tian L et al., 2010), and data reported by Merck Research 127 
Laboratories. Also, the chosen concentration of the drug was the one able to maximize 128 
plasma DPPIV inhibition in order to get full effect. Mice were monitored daily for urine 129 
glucose using Glucocard strips during the whole study (Menarini, Barcelona, Spain). 130 
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Thymic glands from NOD mice were obtained after 4 weeks (at approximately 10-12 131 
weeks of age, n=5) and 6 weeks (at approximately 12-14 weeks of age, n=5) of 132 
treatment with MK626. Thymic glands were also obtained from a NOD mouse control 133 
group for each time point (n=10). Samples were snap-frozen in an isopentane/cold 134 
acetone bath and were kept at -80 ⁰C until RNA extraction.  135 
 136 
2.3. Microarray experiments 137 
RNA was obtained from the thymi of pre-diabetic treated mice at 4 and 6 weeks of 138 
treatment, using RNeasy Micro (QIAGEN, Hilden, Germany). Thymic glands were also 139 
obtained from a NOD mouse control group for each time point. RNA quality (2100 140 
Bioanalyzer, Agilent Technologies Inc., Santa Clara, CA) was optimal for microarray 141 
experiments (RIN between 6 and 8). cDNA was synthesized with 50-100 ng of total 142 
RNA using the WT expression kit (Ambion, Applied Biosystems, CA, USA), 143 
fragmented and labeled with the Terminal labeling kit (Affymetrix, Inc. Santa Clara, 144 
CA), purified (GeneChip® Sample Cleanup Module, Affymetrix), fragmented and 145 
checked to verify its integrity. Mouse Gene1.1 ST 16 array plates (28.853 genes) were 146 
hybridized and scanned by an Affymetrix G3000 Gene Array Scanner. 147 
 148 
2.4. Statistical analyses of microarrays 149 
Raw expression values obtained from CEL files were pre-processed using the Robust 150 
Multiarray Averaging method (Irizarry et al., 2003). These normalized values were 151 
used for all subsequent analyses. Experimental data have been uploaded into 152 
ArrayExpress for the European Bioinformatics Institute (EBI, 153 
www.ebi.ac.uk/aerep/login; E-MTAB-2082). Data were subjected to non-specific 154 
filtering to remove low signal and low variability genes. Conservative (low) thresholds 155 
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were used to reduce possible false negative results. The selection of differentially 156 
expressed genes was based on a linear model analysis with empirical Bayes 157 
modification for the variance estimates, as previously described (Smyth, 2004). This 158 
method is similar to using a ‘t-test’ with an improved estimate of the variance. To 159 
account for the multiple testing probability effects arising when many tests (one per 160 
gene) are performed simultaneously, p-values were adjusted to obtain strong control 161 
over the false discovery rate using the Benjamini-Hochberg method (Benjamini and 162 
Hochberg, 1995). Genes were considered differentially expressed based on the 163 
following criteria: genes with an adjusted p-value <0.05 and a logarithmic fold change 164 
(log2FC) ≥ 0.8 were considered up-regulated, whereas genes with log2FC ≤ -0.8 were 165 
considered down-regulated.  166 
Genes were classified into functional categories on the basis of Gene Ontology 167 
(GO) nomenclature (www.geneontology.org) and other annotations provided by NCBI 168 
Entrez (www.ncbi.nml.nih.gov/gene) database and data from general literature. The 169 
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems ®) (www.ingenuity.com) was 170 
used to identify the canonical pathways from the IPA library that were most significant 171 
to the data sets. Data from the IPA are expressed as a p-value < 0.05 calculated by using 172 
the right-tailed Fisher’s Exact Test. The Fisher test is used to compare the number of 173 
user-specified molecules of interest that participate in a given function, relative to the 174 
total number of occurrences of these molecules in all functional annotations in 175 
Ingenuity’s knowledge base. 176 
 177 
2.5. Quantitative RT-PCR 178 
Total RNA from each sample was reverse-transcribed with a High Capacity cDNA 179 
Reverse Transcription Kit (Applied Biosystems). cDNA synthesis reactions were 180 
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carried out using random hexamers (0.5 µg/µl, BioTools, Valle de Tobalina, Madrid, 181 
Spain) and reverse transcriptase Moloney-murine-Leukaemia-virus (M-MLV) (200 182 
U/µl, Promega, Madison, WI). qRT-PCR assays were performed under Taqman 183 
universal assay on a LightCycler® 480 (Roche, Mannheim, Germany) using the 184 
following TaqMan assays: Plunc (Mm00465064_m1), Ear1 (Mm03059811_g1), Reg3g 185 
(Mm01181783_g1), Ccl11 (Mm00441238_m1), Nov (Mm00456855_m1), Muc1 186 
(Mm00449604_m1), Ccl6 (Mm01302419_m1), Sprra1 (Mm00845122_s1), Gfra2 187 
(Mm00433584_m1), Clec7a (Mm01183349_m1), C3ar1 (Mm01184110_m1), Lgmn 188 
(Mm01325250_m1), Ccl21 (Mm03646971_gH), Ccl3 (Mm00441259_g1), Ccl9 189 
(Mm00441260_m1), Cd4 (Mm00442754_m1), Epcam (Mm00493214_m1), Rag2 190 
(Mm01270938_m1), Dpp4 (Mm00494549_m1) and Cd3d (Mm00442746_m1). 191 
Relative quantification was performed by normalizing the expression for each gene of 192 
interest to that of the housekeeping gene Gapdh (Mm99999915_g1), as described in the 193 
2-∆Ct method (Livak and Schmittgen, 2001), and was referred as arbitrary units. 194 
 195 
2.6. Enzyme-linked immunosorbent assays 196 
Protein lysates were obtained from the thymi of pre-diabetic mice at 6 weeks of 197 
treatment with MK626. Frozen tissues were crushed with a mortar and pestle in liquid 198 
nitrogen and homogenized in phosphate buffered saline with protease inhibitor cocktail 199 
(Thermo Scientific, MA, USA) using a 21G needle and syringe at 4 ºC. Homogenates 200 
were centrifuged at 5000 × g for 5 min, and supernatants were collected and stored at -201 
80 °C until use. Protein concentration of the lysates was determined using the 202 
Bicinchoninic acid (BCA) assay (Thermo Scientific) and the assessment of PLUNC, 203 
CCL21 (Abbexa Ltd., Cambridge, UK) and REG3G (Cusabio, Hubei, China) was 204 
performed by the corresponding ELISAs. The amount of protein of interest was 205 
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normalized to the amount of total protein for each sample, and results were expressed 206 
as pg of protein of interest/mg of total protein. 207 
 208 
2.7. Isolation of thymic epithelial cells (TECs) and gene expression analysis by qRT-209 
PCR  210 
For the analysis of expression of β-cell autoantigens and Aire in TECs, 5 treated under 211 
the aforementioned MK626 administration for 6 weeks and 5 control female NOD/LtJ 212 
mice were used. Thymic glands of NOD mice, with or without MK626 treatment, were 213 
obtained. Extraction and digestion of the individual thymus were performed according 214 
to Seach N. et al. (Seach et al., 2012). Thymic cellular suspension was passed through 215 
70-µm nylon mesh filter before staining and sorting. The staining was performed using 216 
anti-EpCAM-PE (0.1 µg/ml, BDbioscience) and anti-CD45-APC (2 µg/ml, 217 
BDbioscience) and then the cellular suspension was sorted selecting CD45 negative 218 
cells and EpCAM positive cells. Collected cells from the sorting were washed twice 219 
with a phosphate buffer and then the pelleted cells were snap frozen in liquid nitrogen. 220 
RNA extraction was performed using the RNAeasyKit (QIAGEN, Hilden, Germany) 221 
according to manufacturer’s instructions. cDNA was obtained by retrotranscription with 222 
the enzyme MMLV according to manufacturer’s instructions (Promega) and using 223 
Oligo-dT primers. qRT-PCR assays were performed using TaqMan universal assay 224 
conditions and using the following TaqMan assays: Gad1 (Mm04207432_g1), Gad2 225 
(Mm00484623_m1), Ins1 (Mm01950294_s1), Ins2 (Mm00731595_gH), and Aire 226 
(Mm00477461_m1). Relative quantification was performed by normalizing the 227 
expression for each gene of interest to that of the housekeeping gene Gapdh 228 
(Mm99999915_g1), as described in the 2-∆Ct method (Livak and Schmittgen, 2001). 229 
 230 
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2.8. Statistical analysis  231 
The analyses of the array data were described in the corresponding subsection. 232 
Statistics was performed using the Prism 5.0 software (Graph-Pad software Inc., San 233 
Diego, CA). Median values between treated and control group were compared using a 234 
non-parametric Mann-Whitney test. A p-value < 0.05 was considered significant. 235 
 236 
3. Results and Discussion  237 
3.1. Effects of CD26/DPPIV inhibition in thymic gene expression profile  238 
A microarray analysis was performed on the thymi of 5 treated and 5 control 239 
NOD mice for each checkpoint (4 and 6 weeks of treatment). One of the samples from 240 
treated group was discarded because quality control post-hybridization was not optimal 241 
for microarray experiments. A total of 58 genes out of the 28,853 mouse genes 242 
represented on the gene chip were differentially expressed in treated mice after 6 weeks 243 
of treatment with MK626 using an adjusted p-value < 0.05. Strikingly, all of these 58 244 
differentially expressed genes were up-regulated. In contrast, after 4 weeks of treatment, 245 
no significant differences in thymic gene expression were found between groups. The 246 
heatmap analysis is represented in Figure 1. 247 
 248 
3.2. Validation of the microarray results by qRT–PCR and ELISA 249 
 250 
Validation by qRT-PCR of the most selected targets confirmed the microarray 251 
findings (Fig. 2). Only minor discrepancies were found: The difference observed in two 252 
over-expressed genes in MK626-treated mice, Sprr1a and Gfra2, do not reach statistical 253 
significance and Ear1 gene showed an inverse tendency with respect the microarray 254 
results, although without significant differences.  255 
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As a control, we also validated the gene expression of some alternative thymus-256 
related gene such as Rag2, Cd4, Cd3d, Epcam and Dpp4 genes by qRT-PCR. Although 257 
microarray data did not show statistical difference between treated and controls for the 258 
expression of the aforementioned genes, qRT-PCR technique showed a significant 259 
increased expression of Epcam (p<0.01), Dpp4 (p<0.01) and Cd3d (p<0.05) in MK626-260 
treated mice (Fig. 2). Moreover, Cd4 and Rag2 gene expression tended to increase in 261 
the treated mice, although the difference was not statistically significant.  262 
 Additionally, the validation of gene expression microarray results was also 263 
achieved at protein level. Quantification of the protein levels of some over-expressed 264 
genes (Plunc, Reg3g and Ccl21) was performed in the thymi of MK626-treated mice by 265 
ELISA technique. Results showed that PLUNC, REG3G and CCL21 protein levels tend 266 
to be increased in treated mice compared to control mice, although the difference was 267 
not statistically significant (Fig.3).  268 
 269 
3.3. Analysis of differentially expressed genes  270 
The differentially expressed genes mainly belonged to categories linked to the 271 
immune system, inflammation and other biological cellular processes according to gene 272 
ontology (GO) categories and data provided by NCBI Entrez database and by the 273 
literature. Genes selected by functional categories are displayed in Table 1. Within the 274 
immune system, the most over-represented categories included innate immunity, 275 
chemotaxis, immunoregulation and antigen presentation.  276 
The Ingenuity Pathway analysis (IPA) identified 5 canonical pathways (Table 2). 277 
Altered pathways in the thymi from treated mice were primarily related to the immune 278 
system. Moreover, IPA analysis also indicated that the most over-expressed genes 279 
encode molecules belonging to inflammatory and immune responses, including those 280 
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linked to immune cell trafficking (Table 3). Gene interactions involved in immune and 281 
inflammation responses (Fig. 4) are represented by the interaction network analysis. 282 
Remarkably, a number of genes that were differentially affected by 283 
CD26/DPPIV inhibition are involved in processes related to differentiation or the 284 
activation of T cells and/or are implicated in the maintenance of immune tolerance. The 285 
discussion section of the present study will focus on those genes implicated in 286 
immunological central tolerance. 287 
 288 
CD26/DPPIV inhibition increases the expression of innate immunity genes in the 289 
thymus of NOD mice. 290 
Treatment with the CD26/DPPIV inhibitor MK626 was associated with higher 291 
expression of genes involved in the innate immunity, such as pattern recognition 292 
receptors (Clec7a, Clec9a, Reg3g) and other anti-bacterial genes (Muc1, Plunc, Lbp, 293 
Csf1r, EARs). Plunc was the most induced gene in our microarray analysis, and 294 
although the exact biological function of this gene is not clearly defined, it may play a 295 
role in innate immunity in the upper respiratory tract (Bartlett et al., 2011). In the 296 
murine thymus, the expression of Plunc gene in the medullary compartment has been 297 
reported (LeClair et al., 2001).  298 
The role of innate immunity in preventing autoimmunity against pancreatic β 299 
cells in T1D is gaining importance. It has been described that a combination of toll–like 300 
receptor 2 (TLR2) tolerization and CD26/DPPIV inhibition can reverse early-onset 301 
diabetes in NOD mice (Kim et al., 2012). In addition, recent studies have reported a key 302 
role of CLEC7a (Dectin-1) protein, which belongs to the C-type lectin-domain 303 
superfamily of pattern recognition receptors, in the establishment of immune tolerance 304 
and in preventing autoimmune diseases, such as T1D. It has been recently demonstrated 305 
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that treatment with zymosan, a fungal wall cell component, protects NOD from T1D. 306 
Zymosan interacts with TLR2 and CLEC7a to induce suppressor cytokines (IL-10, 307 
TGF-β) by antigen presenting cells (APCs), thus promoting the activation and 308 
expansion of Tregs (Dillon et al., 2006; Karumuthil-Melethil et al., 2008). It is 309 
noteworthy that in the present study, Clec7a gene was found to be over-expressed in the 310 
thymi of treated mice. 311 
Another up-regulated gene expression in MK626-treated mice was Muc1. This 312 
gene encodes a transmembrane glycoprotein expressed on the surface of most types of 313 
epithelial cells that plays an essential role in the protection of mucosal barriers 314 
(Mockensturm-Gardner et al., 1996). In the immune system, MUC1 protein (or mucin) 315 
is expressed on the surface of dendritic cells (DCs), monocytes and activated T cells. 316 
MUC1 was shown to inhibit T cell proliferative response inducing an anergy-like state. 317 
MUC1 also acts in lymphocyte trafficking due to its adhesion and/or anti-adhesion 318 
properties (Agrawal and Longenecker, 2005). In addition, the promiscuous expression 319 
of MUC1 by mTECs has been described to confer a state of immune tolerance (Acres et 320 
al., 2000; Cloosen et al., 2007). More recently, there has been a report of increased 321 
expression of MUC1 on Tregs after CD3 stimulation and that CD3/MUC1 co-322 
stimulation leads to Treg expansion (Konowalchuk and Agrawal, 2001). Hence, MUC1 323 
may have implications for immune tolerance through its involvement in the modulation 324 
of T cell responses and Tregs proliferation. 325 
Data obtained in the present study suggest a possible role of CD26/DPPIV 326 
inhibition in the innate immune response and support the hypothesis that innate 327 
immunity has a protective role in T1D. The targeting of CD26/DPPIV by MK626 328 
increases transcripts of genes related to innate immunity and may improve 329 
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immunological central tolerance through the impairment of T cell responses and the 330 
enhancement of Tregs expansion. 331 
 332 
Chemotaxis genes were over-expressed in the thymus by MK626 treatment. 333 
The microarray data revealed elevated expression of genes encoding some 334 
chemokines in treated NOD mice (Table 1). This group represented one of most over-335 
expressed categories affected by CD26/DPPIV inhibition. Several chemokines 336 
expressed in the thymus have been described as substrates of the peptidase activity of 337 
CD26/DPPIV, which either inactivates or alters the chemotactic activity of these 338 
chemokines. In the microarray analysis, the expression levels of genes encoding several 339 
DPPIV-processed chemokines, such as CCL11 and CCL3, were increased in MK626-340 
treated mice. However, genes that encode other chemokines not targeted by 341 
CD26/DPPIV activity, such as CCL21, CCL9, CCL6 and CXCL16, were also over-342 
expressed, suggesting that these differential effects in gene expression of these 343 
chemokines may be independent of CD26/DPPIV enzymatic activity.  344 
The migration of developing thymocytes within the thymus is crucial for T cell 345 
repertoire selection and requires complex interactions between thymocytes and the 346 
surrounding microenvironment (Ruiz et al., 1996). It is well known that chemokines are 347 
key elements in intrathymic organization and the migration of thymocytes during their 348 
maturation, thus contributing to the sorting of positively and negatively selected 349 
thymocytes (Annunziato et al., 2001). Therefore, the up-regulation of the Ccl21 gene 350 
expression represents one of the most important differential effects caused by 351 
CD26/DPPIV inhibition in this category due to its effects on thymocyte migration 352 
processes. The chemokine CCL21 is chemotactic agent for thymocytes and naïve T 353 
cells and binds to chemokine receptor 7 (CCR7). CCR7 and its ligands, CCL21 and 354 
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CCL19, play an important role in lymphoid cell trafficking and the structural 355 
organization of lymphoid tissues, and they contribute to both immunity and tolerance 356 
(Förster et al., 2008). Several studies have demonstrated the role of the CCR7 axis in 357 
thymic compartmentalization by coordinating migratory events during T cell 358 
development (Ueno et al., 2004). In the thymus, the chemotactic interaction between 359 
CCR7 expressed by positively selected CD4+ and CD8+ thymocytes and CCL21 360 
produced by mTECs is essential for the migration of these thymocytes from the cortex 361 
to the medulla. This thymocyte migration process mediated by the CCR7 axis 362 
contributes to the negative selection of self-reactive thymocytes and is crucial in the 363 
establishment of a self-tolerant T cell repertoire (Nitta et al., 2009). A deficiency of 364 
CCR7 or its ligands increases the risk for the development of autoimmune diseases, 365 
including T1D (Misslitz et al., 2007). The present microarray analysis revealed that 366 
gene expression levels of Ccr7 and Ccl19 were also up-regulated in treated NOD mice, 367 
but the differences were not statistically significant. 368 
 The Ccl11 gene was also significantly over-expressed in treated NOD mice. This 369 
chemokine, also known as eotaxin, is constitutively expressed in the thymus 370 
(Rothenberg et al., 1995) and is cleaved by CD26/DPPIV proteolytic enzyme (Struyf et 371 
al., 1999) affecting its biological activity. CCL11 displays a chemotactic selective 372 
activity for eosinophils, and it has been reported that the inhibition of CD26/DPPIV 373 
induces an in vivo recruitment of human eosinophils (Forssmann et al., 2008). 374 
Moreover, a recent report described an increase in the secretion of eosinophil-associated 375 
RNAases (EARs) from mouse eosinophils due to eotaxin (Shamri et al., 2012). EARs 376 
from intracellular granules are eosinophil ribonucleases and represent the major source 377 
of eosinophilic secretory effector protein participating in allergic diseases and host 378 
immunity (Rosenberg et al., 2001). It is of note that the gene expression levels of 379 
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several EAR genes (Ear1, Ear10, Ear11) were increased in the present microarray 380 
study. Therefore, the elevated expression of Ccl11 and Ear genes in the thymus may 381 
reflect an increased number of eosinophils due to CD26/DPPIV inhibition. Notably, 382 
eosinophils have been shown to be recruited in the thymus during MHC class I-383 
restricted T cell selection, implying an immunomodulatory role for these cells (Throsby 384 
et al., 2000). In addition, it is known that self-reactive T cells are depleted by apoptosis 385 
during intrathymic selection. The clearance of millions of these apoptotic thymocytes is 386 
important for thymic development and is achieved by thymus resident macrophages and 387 
DCs (Esashi et al., 2003). However, recent data suggest a direct contribution of 388 
eosinophils and neutrophils, which are recruited to the sites of extensive apoptosis to 389 
maximize the efficiency of apoptotic cell removal (Kim et al., 2010). Moreover, it has 390 
been demonstrated that the rapid removal of apoptotic cells is crucial for preventing 391 
inflammatory and autoimmune responses (Sarang et al., 2013).  392 
Expression levels of other genes encoding chemokines were also significantly 393 
increased in our treated mice. These chemokines included CCL3 (MIP-1α), CCL6 394 
(C10/MRP-1) and CCL9 (MIP-1γ/MRP-2), which have also been shown to have 395 
chemotactic activity, primarily for monocyte-macrophages (CCL3, CCL6, CCL19), as 396 
well as for eosinophils (CCL3, CCL6) and neutrophils (CCL3, CCL9) (Coelho et al., 397 
2007; Maurer and von Stebut, 2004). Thus, these chemokines may also be involved in 398 
apoptotic cell clearance. 399 
Taken together, our data suggest that CD26/DPPIV inhibition by MK626 400 
treatment may have a key role in thymocyte trafficking through the modification of the 401 
expression profile of thymic microenvironmental chemokines contributing to the 402 
enhancement of negative selection. These data support the results obtained in the IPA 403 
analysis in which 20 molecules were found to be involved in immune cell trafficking 404 
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(Table 3). Alternately, MK626 treatment may enhance the clearance of apoptotic cells 405 
generated during thymocyte selection through the recruitment of eosinophils. 406 
 407 
Targeting CD26/DPPIV induces the expression of antigen presentation- and 408 
immunoregulation-related genes in the thymus of treated mice. 409 
As shown in Table 1, treated NOD mice showed a higher expression of genes 410 
involved in antigen presentation and the regulation of immune responses, notably 411 
Fcgr2b and Lilrb4 genes.  412 
 The protein encoded by Fcgr2b (Fc receptor, IgG, low affinity IIb) gene belongs 413 
to the family of low affinity receptors for the Fc portion of immunoglobulin gamma 414 
complex. These receptors are involved in a variety of effector and regulatory functions 415 
such as the phagocytosis of immune-complexes from the circulation and the modulation 416 
of antibody production by B cells. In contrast to other members of this family, FcγRIIB 417 
acts as a negative regulator of the immune response, limiting T cell activation by 418 
inhibiting both antigen processing and DC activation (Desai et al., 2007) as well as by 419 
suppressing the activation of autoreactive B cells (Nimmerjahn and Ravetch, 2007). A 420 
deficiency in the inhibitory FcγRIIB leads to imbalanced immune responses that result 421 
in the development of autoimmune diseases (Nimmerjahn and Ravetch, 2006). 422 
Therefore, FcγRIIB potentially may contribute to the maintenance of tolerance and 423 
protection from autoimmune diseases.  424 
Another significantly over-expressed gene was Lilrb4. The encoded protein, also 425 
known as immunoglobulin-like transcript 3 (ILT-3), is a member of the leukocyte Ig-426 
like receptor family (LIR), which is selectively expressed by APCs such as DCs, where 427 
it binds to MHC class I molecules and transduces a negative signal that inhibits 428 
stimulation of the immune response (Kim-Chulze et al., 2006). It is known that 429 
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inhibitory activity of Tregs is determinant in the prevention of autoimmune disorders. A 430 
distinct population of these lymphocytes with a CD8+ CD28- phenotype has been 431 
characterized and is referred to as T suppressor cells (Chang et al., 2002). These 432 
lymphocytes are FOXP3+ and MHC class I-restricted, and they tolerize APCs by 433 
inducing the up-regulation of inhibitory receptors, such as LILRB4/ILT-3 and 434 
LILRB/ILT-4, as well as by inhibiting CD40 signaling in APCs. These tolerogenic 435 
LILRB4/ILT-3 DCs induce an anergic state in CD4+ T cells, resulting in the loss of their 436 
proliferative and differentiation capacity and the transformation of these cells into 437 
Tregs, which continue the cascade of suppression by tolerizing other DCs (Kim-Chulze 438 
et al., 2006; Manavalan et al., 2003). Therefore, the up-regulation of LILRB4/ILT-3 439 
appears to be a general characteristic of tolerogenic DCs and may be important for 440 
induction of antigen-specific tolerance. 441 
Notably, the IPA analysis identified an altered pathway implicated in 442 
immunoregulation: IL-10 signaling. IL-10 is an anti-inflammatory and 443 
immunoregulatory cytokine. It is expressed by many immune cell types of both the 444 
adaptive and innate immune systems, supporting its crucial role as a regulator of 445 
immune responses. The main producers of IL-10 are Tregs, and this cytokine enhances 446 
the differentiation of these IL-10-secreting Tregs cells, thus providing a positive 447 
regulatory feedback (Saraiva and O’Garra, 2010). In addition, IL-10 can be induced by 448 
CLEC7a (dectin-1) stimuli. Remarkably, the Clec7a gene expression was up-regulated 449 
in the present microarray analysis. A potent effect for IL-10 in preventing autoimmunity 450 
has been described, although its role in the development of diabetes is controversial. In 451 
NOD mice, some studies have demonstrated that IL-10 is important in establishing 452 
immune tolerance, whereas others have demonstrated accelerated diabetogenic 453 
autoimmune responses (Saraiva and O’Garra, 2010; Tai et al., 2011).  In our present 454 
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study, the lack of IL-10 gene over-expression in the thymi of treated mice can be 455 
attributed to the low sensitivity of the arrays used to detect cytokines (Park and Stegall, 456 
2007). 457 
Thus, CD26/DPPIV inhibition may exert a potent immunosuppressive activity 458 
on T cells by inducing tolerogenic DCs through the over-expression of inhibitory 459 
receptors, such as FcγRIIB and LILRB4/ILT-3. Remarkably, these encoded proteins are 460 
not cleaved by CD26/DPPIV, and these results support the hypothesis that the 461 
proteolytic activity of DDPIV is not essential for its co-stimulatory function in T cell 462 
response (Boonacker et al., 2002).  463 
 464 
MK626 treatment increases the expression of genes related to other cell functions  465 
Several genes regulating biological processes, such as cell adhesion, cell 466 
migration and cell proliferation, were more highly expressed in treated mice.   467 
The interactions between thymocytes and the microenvironment are essential for 468 
the intrathymic migration of thymocytes. Interestingly, the impairment of thymocyte 469 
migration through the thymic microenvironment has been reported in NOD mice (Cotta-470 
de-Almedia et al., 2004).  The enzymatic activities of metalloproteinases are involved in 471 
thymocyte-stroma interactions by remodeling of the extracellular matrix (ECM). A role 472 
for metalloproteinases in thymic T cell development has been recently demonstrated 473 
using Adam8-deficient mice (Gossens et al., 2010). ADAM8 is a member of the 474 
Disintegrin and Metalloproteinase (ADAM) family of proteins. A variety of biological 475 
processes involving cell-cell and cell-matrix interactions have been implicated. In the 476 
thymus, ADAM8 is expressed by TECs, principally by mTECs, and is involved in 477 
intrathymic T cell migration through the aforementioned remodeling of the ECM. 478 
Interestingly, data from the present microarray experiments revealed increased 479 
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transcripts of Adam8 gene in treated mice and strongly support the contention that 480 
CD26/DPPIV inhibition may enhance the migration of positively selected thymocytes 481 
to the medulla, which is essential for the establishment of central tolerance.  482 
 483 
3.4. Role of MK626 treatment in altering the expression of β-cell autoantigens and Aire 484 
in the thymi of NOD mice. 485 
To determine the potential mechanisms by which the CD26/DPPIV inhibition is 486 
involved in T1D prevention, we next investigated whether MK626 treatment alters the 487 
expression of genes encoding islet autoantigens, such as Gad1, Gad2, Ins1 and Ins2 as 488 
well as the autoimmune regulator Aire, in purified TECs obtained at 6 weeks using 489 
qRT-PCR.  490 
 491 
MK626 treatment does not alter β-cell autoantigens and Aire expression in TECs 492 
As shown in Figure 5, no differences were observed in the gene expression of 493 
Gad1 (glutamic acid decarboxylase), Ins2 (proinsulin) and Aire (transcription factor 494 
autoimmune regulator) in TECs between MK626-treated and control mice. Gad2 and 495 
Ins1 showed a very low expression in either treated and control animal. These findings 496 
are consistent with data reported in the literature. INS2 is the major isoform recognized 497 
by T cells in NOD mouse and is expressed in both β cells and the thymus, while the 498 
expression of Ins1 in the thymi has been debated (Thébault-Baumont et al., 2003).  499 
The thymus is involved in the establishment of tolerance to peripheral Ags. The 500 
expression of a broad repertoire of TRAs within the thymus has been termed 501 
promiscuous gene expression (Sospedra et al., 1998). Data suggests that this expression 502 
of TRAs by TECs, mainly mTECs, play a role in thymic central tolerance through 503 
clonal deletion of self-reactive thymocytes (Derbinski et al., 2001; Kyewski et al., 504 
2002). In T1D, insulin represents one of the principal targets in the development of 505 
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diabetogenic autoimmunity and their presentation in the thymus promotes the deletion 506 
of self-reactive thymocytes (Kent et al., 2005; Nakayama et al., 2005). Aire is 507 
responsible for mediating central tolerance of peripheral self-Ags because it induces the 508 
expression of many of these TRAs by TECs, which are processed and then presented on 509 
surface to MHC/HLA (Mathis and Benoist, 2009; Rizzi et al., 2006). It has been 510 
reported that the expression of Aire and TRAs by TECs in NOD model is much lower 511 
than normal (Balb/c) TECs (Chen et al., 2008) and its expression varies with age and 512 
with the onset of T1D (Fornari et al., 2010; Oliveira et al., 2013). So, recent data 513 
suggest that thymic down-regulation of Aire in young NOD mice (pre-diabetic 514 
checkpoint) precedes the onset of T1D (Fornari et al., 2010), whereas Aire expression 515 
during the perinatal period is important to prevent autoimmunity in this model (Guerau-516 
de-Arellano et al., 2009).  517 
Taken together, we found that gene expression of islet autoantigens and the 518 
autoimmune regulator Aire is not influenced by CD26/DPPIV inhibitor treatment, 519 
unless in the late preclinical stage of the disease in NOD mice. Although further studies 520 
with more amount of thymic tissue analysed are required to confirm our findings, it 521 
maybe also needed to investigate whether MK626 affects the expression of these genes 522 
in a much earlier phase of the pre-diabetic state, including the perinatal period. 523 
524 
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 525 
4. Conclusion 526 
In a previous study, our group found that the CD26/DPPIV inhibitor MK626 527 
decreased the incidence of T1D and reduced islet lymphocyte infiltration in pre-diabetic 528 
NOD mice. Moreover, in peripheral compartment, MK626 increases CD26 expression 529 
in the CD8+ TEM T cells. Indeed, in vitro assays revealed an immunosuppressive role for 530 
CD8+ TEM cell subset that may be involved in the protection against autoimmunity to β-531 
cells. In the current study, we demonstrate for the first time that the expression of 532 
immune-related genes, especially those potentially involved in central tolerance, is 533 
modified in the thymus of MK626-treated mice. Our data from microarray analysis 534 
suggest that targeting CD26/DPPIV may affect immunological central tolerance 535 
mechanisms through several possible pathways, including the following: 1) contributing 536 
to the migration of thymocytes to the thymic medulla, thus enhancing negative 537 
selection; 2) increasing the efficiency of clearance of apoptotic cell generated during 538 
positive and negative thymic selection; 3) limiting T cell activation and responses; 4) 539 
inducing tolerogenic DCs; and 5) enhancing natural Tregs generation and function. 540 
Altogether, the inhibition of CD26/DPPIV may enhance the efficiency of deleting self-541 
reactive thymocytes and modulate T cell responses and, consequently, may reduce the 542 
diabetogenic autoimmune response. However, the effects of DPPIV inhibition regarding 543 
T1D prevention do not seem to involve modifications of Aire and β-cell autoantigens 544 
expression. 545 
Our results provide more insight into the understanding of the mechanisms 546 
through which targeting CD26/DPPIV prevents and even reverses T1D in NOD mice. 547 
However, further functional studies are needed to confirm the present findings. 548 
 549 
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Table 1.Functional categorization of transcripts that were differentially expressed 889 
in treated NODmice  890 
 891 
Function Gene Locus  
 ID 
Protein name Log2 
FC 
adj 
p-value 
al/prol*  Other functions 
Innate 
immunity 
Plunc 18843 BPI fold containing family A, 
member 1 
4.8334 0.0108 No* Inflammatory response  
 Reg3g 19695 Regenerating islet  
derived protein 3γ· 
2.8724 0.0174 No Inflammatory response  
 Ear11 93726 Eosinophil-associated, 
ribonuclease A family, member 
11 
1.9618 0.0298 No Inflammatory response; 
Chemotaxis 
 Ear10 93725 Eosinophil-associated, 
ribonuclease A family, member 
10 
1.5329 0.0174 No Inflammatory response  
 Ear1 13586 Eosinophil-associated, 
ribonuclease A family, member1/ 
Eosinophil cationic protein 1 
1.4553 0.0159 No Inflammatory response  
 Clec7a 56644 C-type lectin domain family 7, 
member A /Dectin-1  
1.3757 0.0298 No Inflammatory response; 
Immunoregulation; 
Phagocytosis; Cell adhesion; 
Signaling 
 Muc1 17829 Mucin -1  1.2602 0.0174 No  Inflammatory response; Cell 
adhesion; Cell growth;  
Signaling; Apoptosis 
 Lbp 16803 Lipopolysaccharide binding 
protein 
1.2689 0.0478 No Inflammatory response;  
Phagocytosis; Chemotaxis; Cell 
motility; Cell migration; 
Signaling 
 Ifitm1 68713 Interferon-induced 
transmembrane protein 1 
1.1397 0.049 Yes Cell adhesion; Cell migration; 
Cell proliferation 
 Clec9a 232414 C-type lectin domain family 9 
member A  
0.8924 0.0439 No Antigen presentation; 
Immunoregulation 
 Csf1r 12978 Macrophage colony-stimulating 
factor 1 receptor 
0.864 0.0437 Yes Inflammatory response; Cell 
proliferation; Cell migration; 
Cell motility; Cell adhesion; 
Signaling 
Chemotaxis Ccl11 20292 Chemokine (C-C motif) ligand 
11/Eotaxin 
1.6042 0.0174 Yes   Cytokine activity; Inflammatory 
response; Cell migration; Cell 
motility; Cell growth; Cell 
proliferation; Signaling 
 Ccl6 20305 C-C motif chemokine 6 1.4969 0.0177 No Cytokine activity; Inflammatory 
response; Cell migration; Cell 
motility 
 Ccl27 20301 Chemokine ligand 27 1.618 0.0177 Yes Cytokine activity  
 C3ar1 12267 C3a anaphylatoxin chemotactic 
receptor 
1.559 0.0298 No Inflammatory response; Antigen 
presentation; Phagocytosis; Cell 
migration; Cell motility; 
Signaling 
 Ccl21 18829 Chemokine ligand 21a 1.1009 0.0298 No Cytokine activity; Inflammatory 
response; Immunoregulation; 
Cell migration;  
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 Ccl3 20302 C-C motif chemokine 3, MIP1α 1.1966 0.0298 Yes Cytokine activity; Inflammatory 
response; Cell migration; Cell 
motility; Signaling; Apoptosis 
 Ccl9 20308 C-C motif chemokine 9, MIP1γ 1.1829 0.0311 No Cytokine activity; Inflammatory 
response 
 Cxcl16 66102 C-X-C motif chemokine 16 0.9195 0.0437 No Cytokine activity; Innate 
immunity; Antigen presentation; 
Cell migration; Cell motility; 
Cell growth  
Immuno 
regulation  
Fcgr2b 14130 Low affinity Ig gamma Fc region 
receptor IIB 
0.9484 0.0339 No Inflammatory response; Antigen 
presentation; Phagocytosis; Cell 
proliferation; Signaling; 
Apoptosis  
 Lilrb4 14728 Leukocyte Ig-like  
receptor subfamily B member 4 
0.9461 0.0341 No Antigen presentation; Signaling 
Antigen  
presentation  
Lgmn 19141 Legumin 0.9826 0.0298 Yes Cell growth; Apoptosis  
Inflammation  Scgb3a1 68662 Secretoglobin family  
3A member 1 
4.4231 0.0241 No Cytokine activity; Cell 
proliferation  
 Sgb1a1 22287 Uteroglobin 4.2748 0.0241 No Cytokine activity; 
Immunoregulation; Cell 
proliferation; Signaling 
 Retnla 57262 Resistin-like alpha 2.2577 0.0341 No  
 Fstl1 14314 Follistatin related  
protein 
1.1499 0.0298 No  Innate immunity; Autoantigen; 
Cell proliferation 
Cell adhesion Itga8 241226 Integrin alpha 8 1.7714 0.0177 Yes Metanephric and Nervous 
system development, 
Extracellular matrix 
organization; Signaling 
 Postn 50706 Periostin 1.3371 0.0174 No  Inflammatory response; 
Extracellular matrix organization 
 Mfap4 76293 Microfibril-associated 
glycoprotein 4 
1.1654 0.0311 Yes Extracellular matrix 
organization; Signaling 
 Adam8 11501 Disintegrin and 
metalloproteinase domain-
containing protein 8 
1.1554 0.033 No Inflammatory response; Innate 
immunity; Chemotaxis; Cell 
migration; Cell motility; 
Signaling; Apoptosis; 
Extracellular matrix organization 
 Col6a2 12834 Collagen alpha-2 (IV) chain  1.1455 0.0298 No Extracellular matrix organization 
 Tgfbi 21810 Transforming growth factor-
beta-induced protein ig-h3 
1.0326 0.0341 Yes Signaling; Extracellular matrix 
organization 
Cell 
proliferation 
/Growth 
Nov 18133 Nephroblastoma overexpressed 
gene/Protein NOV homolog 
1.6978 0.0174 No Cell growth  
 Tppp3 67971 Tubulin polymerization 
promoting protein family 
member 3 
1.42 0.0298 Yes  
 Smpd3 58994 sphingomyelinphosphodiesterase 
3 
1.1967 0.0174 No Signaling; Apoptosis 
 Atf3 11910 Activating transcription factor 
3/Cyclic AMP-dependent 
transcription factor 3  
0.8808 0.0298 No Inflammatory response; 
Transcription factor; Apoptosis 
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 892 
Apoptotic 
process 
Timp1 21857 Metalloproteinase inhibitor 1 1.4433 0.0341 No Erythrocyte maturation; Cell 
proliferation 
 Clca2 80797 Chloride channel calcium 
activated 2 
1.324 0.0413 No  
 
Nervous 
system   
 
Gabrp 216643 Gamma-aminobutyric acid 
(GABA) A receptor, pi 
1.9095 0.0298 No   
 Efhd1 98363 EF-hand domain-containing 
protein D1 
1.3264 0.0341 No  
 Gas7 14457 Growth arrest specific protein  7 1.1794 0.0435 Yes Cytoskeleton  
 Duoxa 1 213696 Dual oxidase maturation factor 1  1.12 0.0298 Yes Cell adhesion 
 Gfra2 14589 Glial cell line derived 
neurotrophic factor family 
receptor alpha2 
1.0545 0.0298 No Signal transduction  
 Mtap1b 17755 Microtubule-associated protein 
1B 
0.9402 0.0413 No Cytoskeleton  
Miscellaneous  
Ion binding  
       
 Cyp2f2 13107 Cytochrome P450,  
family 2, subfamily f, 
polypeptide 2 
4.07 0,.0311  No  
 Cyp4a12b 13118 Cytochrome P450,  
family 4, subfamily a, 
polypeptide 12 
3.0037 0.0298 No  
 Cyp2a5 13087 Cytochrome P450,  
family 2, subfamily a, 
polypeptide 5 
2.3177 0.0159 No  
 Cyp2a4 13086 Cytochrome P450,  
family 2, subfamily a, 
polypeptide 4 
1.9005 0.0298 No  
 Mt2 17750 Metallothionein 2 1.4602 0.0405 No  
Olfaction  Olfr111 545205 Olfactory receptor 111 1.5254 0.0298 No  Signal transduction 
Keratinization Sprr2a1 20755 Small proline-rich  
protein 2A1 
1.5064 0.0298 No  
 Sprr1a 20753 Small proline-rich  
protein 1A/Cornifin-A 
1.1202 0.0298 No  
Protein  
transport  
Slc15a3 65221 Solute carrier family 15  0.89 0.0298 No  
Bio 
mineralization  
Aspn 66695 Asporin 1.1079 0.0298 Yes  
Blood 
coagulation  
F3 14066 Coagulation factor III /Tissue 
factor 
1.1209 0.0477 No  
Cytoskeleton Acta2 11475 Actin, aortic smooth muscle 1.3261 0.0413 No  
 Tagln 21345 Transgelin 0.9713 0.0311 No  
Histidine 
metabolism  
Hal 15109 Histidine ammonia lyase 1.11209 0.0298 Yes  
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Genes significantly up-regulated by targeting CD26/DPPIV are listed, with the mean 893 
difference between the groups (Fold Change; FC) and the false discovery rate estimated 894 
by the Benjamini-Hochberg method (adjusted p-value: < 0.05). *Al/prol is referenced to 895 
the presence in peptide of alanine and proline in the penultimate position.  896 
 897 
 898 
 899 
 900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
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Table 2. Top over-represented pathways identified in treated NOD mice by Ingenuity 921 
Pathway Analysis (IPA)  922 
 923 
 924 
 925 
 926 
 927 
 928 
 929 
Immune Canonical Pathways among the “Top 20” biological canonical pathways 930 
resulting from IPA analysis. p-value calculated by the Ingenuity algorithm is given.  931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
 946 
 947 
 948 
Top IPA canonical pathways  (p-value) 
Agranulocyte adhesion and diapedesis (1.29E-07) 
Granulocyte adhesion and diapedesis (1.23E-06) 
Hepatic fibrosis/Hepatic stellate Cell Activation (1.58E-03) 
Communication between innate and adaptive immune cells (2.07E-02) 
IL- 10 signaling (2.4E-02)  
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Table 3. Top biological functions identified in treated NOD mice by Ingenuity Pathway 949 
Analysis (IPA) 950 
 951 
 952 
 953 
Numbers of molecules involved in each biological function are shown. Data are 954 
expressed as a p-value < 0.05.  955 
 956 
 957 
 958 
 959 
 960 
 961 
 962 
 963 
 964 
 965 
 966 
 967 
Disease and disorders    
Name P-value Molecules  
Inflammatory response 
Immunological disease  
Gastrointestinal disease  
Ophthalmic disease 
Respiratory disease  
3.49E-09 – 1.83E-02  
7.32E-08 – 1.73E-02  
9.48E-08 – 1.83E-02  
9.48E-08 – 7.38E-03  
5.27E-06 – 1.47E-02  
27 
21 
21 
11 
18 
Molecular and cellular functions    
Name P-value Molecules 
Cellular Movement  
Cell-To-Cell Signaling and Interaction  
Cellular Function and Maintenance 
Cellular Assembly and Organization  
Cellular Development 
5.31E-10 – 1.83E-02  
2.98E-08 – 1.83E-02  
2.19E-06 – 1.47E-02  
2.85E-05 – 1.83E-02 
6.68E-05 – 1.83E-02 
31 
24 
22 
17 
24 
Physiological System Development and Function   
Name P-value Molecules 
Immune Cell Trafficking  
Hematological System Development and 
Function  
Tissue Morphology  
Tissue Development 
6.08E-10 – 1.83E-02  
1.67E-08 – 1.83E-02  
 
1.67E-08 – 1.47E-02  
2.85E-05 – 1.83E-02  
20 
28 
 
27 
25 
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 968 
Figure 1. Heatmap of thymic gene expression profile from NOD mice. Rows 969 
correspond to differentially expressed genes, and columns represent each thymus 970 
sample from control (red columns) and treated (blue columns) NOD mice. Data were 971 
row-centered by subtracting the row-mean from each value so that under- and 972 
overexpression are indicated by negative (red) and positive (blue) values. C: Control 973 
group; T: Treated group.   974 
 975 
Figure 2. Validation of the gene expression profile. Relative expression levels measured 976 
by qRT-PCR of selected genes in control (C, n=5) and treated (T, n=5) groups. Results 977 
are expressed as mean + SEM. Non parametric Mann-Whitney test was used for the 978 
evaluation of statistical significance. Significance levels, *p < 0.05, **p < 0.01. 979 
 980 
Figure 3. Analysis of the gene expression profile at protein level. Levels of PLUNC, 981 
CCL21 and REG3G measured by ELISAs in control (C, n=5) and treated (T, n=5) 982 
groups. Results are expressed as pg of protein of interest/mg of total protein (mean + 983 
SEM). Non parametric Mann-Whitney test was used for the evaluation of statistical 984 
significance. 985 
 986 
Figure 4. Gene network generated by Ingenuity Pathway Analysis (IPA). IPA was 987 
applied to create an inter-related gene network. Gene interactions linked to the immune 988 
and inflammatory responses are represented. Interacting nodes are defined by either 989 
direct relationships (solid arrows) or indirect relationships (dashed arrows). The 990 
direction of the arrows shows the direction of the interaction. Green molecules indicate 991 
higher expression in treated NOD mice than in control mice at the gene level.  992 
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 993 
Figure 5. Gene expression levels of islet autoantigens and Aire in thymic epithelial cells 994 
(TECs) from MK626-treated and control mice. TECs obtained from treated and control 995 
group (≈ 12 weeks old) were purified after 6 weeks of treatment. Quantitative qRT- PCR 996 
results for Gad1, Ins2 and Aire genes in treated (black bars) and in control mice (white 997 
bars). Gene expression signals were normalized to Gapdh. Data are presented as the 998 
mean + SEM. Non parametric Mann-Whitney test test was used for the evaluation of 999 
statistical significance. 1000 
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Highlights 
• Treatment with DPPIV inhibitors may contribute to the prevention of T1D. 
• Expression of immune –related genes is modified in the thymi of NOD mice by 
MK626. 
• MK626 treatment increases the expression of genes involved in central 
tolerance.  
• DPPIV inhibitor treatment does not alter β-cell autoantigens and Aire expression 
in TECs. 
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